Specialty Pharmacy

RAND Corporation projects biosimilars to cause an approximately 4% reduction in total US biologic spending from 2014 to 2024.

While the Ebola scare has started to fade away in the United States, the crisis continues to devastate West Africa, where the death toll has climbed above 5000 with more than 14000 confirmed and suspected cases.

According to researchers, chemotherapy parity laws ignore the real question of cost versus quality. At the same time, these laws promote anticompetitive practices that affect community oncologists.

Enhancing supportive care improves the chances of a patient surviving an Ebola infection.

Salveo currently manages approximately $400 million in annual drug spend.

A New York City physician who became infected with Ebola after treating patients in West Africa was released from the hospital after being declared virus free.

Cost of medication causes financial burden for nearly two-thirds of patients.

A potential Ebola outbreak in Senegal was snuffed out thanks in part to an innovative text-messaging program originally intended to help patients with diabetes manage their disease.

Researchers determine there may be an opportunity to reduce chemotherapy in pediatric patients with hepatoblastoma.

Women may need more frequent ART doses to prevent HIV transmission than men, a mathematical model suggests

Investigational medication may lead to a promising future for the treatment of the disease.

Gilead Sciences, Inc., has submitted a new drug application to the FDA for its investigational single-tablet regimen for HIV infection in adult patients.

Filoviruses such as the Ebola and Marburg viruses edit the genetic material of the individuals they infect, according to the results of a recent study.

As one of the first areas in the field, nuclear pharmacy is a prototype of specialty pharmacy practice. Specialty Pharmacy Times reviews the history and some of the fundamentals of nuclear pharmacy.

The World Health Organization is criticizing the drug industry for delaying the development of an Ebola vaccine.

Thomas Cohn, chief strategy officer at Armada Health Care, discusses how Armada is changing to meet the needs of the tumultuous Affordable Care Act era.

The FDA today approved a drug previously granted Orphan Drug Designation for the treatment of gastric cancer after prior chemotherapy.

An experimental ovarian cancer treatment failed to demonstrate statistically significant improvements in overall survival during a phase 3 trial.

With concerns of a potential Ebola outbreak in the United States still heightened, a pharmaceutical disaster response group is readying pharmacists with a series of resources on the virus.

An investigational HIV drug developed by Merck exhibited a strong overall safety and efficacy profile in a recently completed phase 2b study.

The severe respiratory illness that infected more than 1000 children across the United States is starting to wane.

QmedRx Vice President of Formulations Scott Karolchyk discusses the resurgence of compounding pharmacies.

Astellas today announced that the FDA has granted orphan drug designation to isavuconazole for the treatment of invasive candidiasis, one of the most frequent invasive fungal infections detected in critically ill patients and a common cause of bloodstream infections.

One of the most crucial roles in the fight to stop the spread of Ebola may be played by a mouse.

T-cell immunotherapy enables stem cell transplants using partially mismatched family members as donors.

When examining the future of the Ebola virus, it is important to understand the epidemic in the context of similar outbreaks that occurred in the relatively recent past.

Discovery offers potential target for future HIV treatments.